Selenoprotein P genetic variants and mrna expression, circulating selenium, and prostate cancer risk and survival

Prostate

Volumn 73, Issue 7, 2013, Pages 700-705

  Penney, Kathryn L ^a,b   Li, Haojie ^c   Mucci, Lorelei A ^a,b   Loda, Massimo ^b,d   Sesso, Howard D ^b   Stampfer, Meir J ^a,b   Ma, Jing ^b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c GLAXOSMITHKLINE   (United States)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

genetic variation; prostate cancer; selenium

Indexed keywords

MESSENGER RNA; SELENIUM; SELENOPROTEIN P;

ADULT; AGED; ALLELE; ARTICLE; BLOOD LEVEL; CANCER RISK; CANCER SURVIVAL; CASE CONTROL STUDY; CAUSAL ATTRIBUTION; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; GENE LOCUS; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEOPLASM; PHYSICIAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; CASE-CONTROL STUDIES; COHORT STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; PROSTATIC NEOPLASMS; RISK FACTORS; RNA, MESSENGER; SELENIUM; SELENOPROTEIN P; SURVIVAL ANALYSIS;

EID: 84876262768     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22611     Document Type: Article

References (22)

1. Duffield-Lillico AJ, Dalkin BL, Reid ME, Turnbull BW, Slate EH, Jacobs ET, Marshall JR, Clark LC,. Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: An analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial. BJU Int 2003; 91 (7): 608-612.
2. Yoshizawa K, Willett WC, Morris SJ, Stampfer MJ, Spiegelman D, Rimm EB, Giovannucci E,. Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. J Natl Cancer Inst 1998; 90 (16): 1219-1224.
3. Li H, Stampfer MJ, Giovannucci EL, Morris JS, Willett WC, Gaziano JM, Ma J,. A prospective study of plasma selenium levels and prostate cancer risk. J Natl Cancer Inst 2004; 96 (9): 696-703.
4. Clark LC, Combs GF Jr, Turnbull BW, Slate EH, Chalker DK, Chow J, Davis LS, Glover RA, Graham GF, Gross EG, Krongrad A, Lesher JL Jr, Park HK, Sanders BB Jr, Smith CL, Taylor JR,. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. JAMA 1996; 276 (24): 1957-1963.
5. Lippman SM, Klein EA, Goodman PJ, Lucia MS, Thompson IM, Ford LG, Parnes HL, Minasian LM, Gaziano JM, Hartline JA, Parsons JK, Bearden JD 3rd, Crawford ED, Goodman GE, Claudio J, Winquist E, Cook ED, Karp DD, Walther P, Lieber MM, Kristal AR, Darke AK, Arnold KB, Ganz PA, Santella RM, Albanes D, Taylor PR, Probstfield JL, Jagpal TJ, Crowley JJ, Meyskens FL Jr, Baker LH, Coltman CA Jr., Effect of selenium and vitamin E on risk of prostate cancer and other cancers: The Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009; 301 (1): 39-51.
6. Hatfield DL, Gladyshev VN,. How selenium has altered our understanding of the genetic code. Mol Cell Biol 2002; 22 (11): 3565-3576.
7. Hill KE, Lloyd RS, Burk RF,. Conserved nucleotide sequences in the open reading frame and 3' untranslated region of selenoprotein P mRNA. Proc Natl Acad Sci USA 1993; 90 (2): 537-541.
8. Meyer HA, Hollenbach B, Stephan C, Endermann T, Morgenthaler NG, Cammann H, Kohrle J, Jung K, Schomburg L,. Reduced serum selenoprotein P concentrations in German prostate cancer patients. Cancer Epidemiol Biomarkers Prev 2009; 18 (9): 2386-2390.
9. Calvo A, Xiao N, Kang J, Best CJ, Leiva I, Emmert-Buck MR, Jorcyk C, Green JE,. Alterations in gene expression profiles during prostate cancer progression: Functional correlations to tumorigenicity and down-regulation of selenoprotein-P in mouse and human tumors. Cancer Res 2002; 62 (18): 5325-5335.
10. Gonzalez-Moreno O, Boque N, Redrado M, Milagro F, Campion J, Endermann T, Takahashi K, Saito Y, Catena R, Schomburg L, Calvo A,. Selenoprotein-P is down-regulated in prostate cancer, which results in lack of protection against oxidative damage. Prostate 2011; 71 (8): 824-834.
11. Steinbrecher A, Meplan C, Hesketh J, Schomburg L, Endermann T, Jansen E, Akesson B, Rohrmann S, Linseisen J,. Effects of selenium status and polymorphisms in selenoprotein genes on prostate cancer risk in a prospective study of European men. Cancer Epidemiol Biomarkers Prev 2010; 19 (11): 2958-2968.
12. Cooper ML, Adami HO, Gronberg H, Wiklund F, Green FR, Rayman MP,. Interaction between single nucleotide polymorphisms in selenoprotein P and mitochondrial superoxide dismutase determines prostate cancer risk. Cancer Res 2008; 68 (24): 10171-10177.
13. Penney KL, Schumacher FR, Li H, Kraft P, Morris JS, Kurth T, Mucci LA, Hunter DJ, Kantoff PW, Stampfer MJ, Ma J,. A large prospective study of SEP15 genetic variation, interaction with plasma selenium levels, and prostate cancer risk and survival. Cancer Prev Res (Phila) 2010; 3 (5): 604-610.
14. Arsova-Sarafinovska Z, Matevska N, Eken A, Petrovski D, Banev S, Dzikova S, Georgiev V, Sikole A, Erdem O, Sayal A, Aydin A, Dimovski AJ,. Glutathione peroxidase 1 (GPX1) genetic polymorphism, erythrocyte GPX activity, and prostate cancer risk. Int Urol Nephrol 2009; 41 (1): 63-70.
15. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med 1989; 321 (3): 129-135.
16. Roberts DG, Morrison TB, Liu-Cordero SN, Cho J, Garcia J, Kanigan TS, Munnelly K, Brenan CJ,. A nanoliter fluidic platform for large-scale single nucleotide polymorphism genotyping. Biotechniques 2009; 46 (3 Suppl): ix-xiii.
17. Setlur SR, Mertz KD, Hoshida Y, Demichelis F, Lupien M, Perner S, Sboner A, Pawitan Y, Andren O, Johnson LA, Tang J, Adami HO, Calza S, Chinnaiyan AM, Rhodes D, Tomlins S, Fall K, Mucci LA, Kantoff PW, Stampfer MJ, Andersson SO, Varenhorst E, Johansson JE, Brown M, Golub TR, Rubin MA,. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst 2008; 100 (11): 815-825.
18. Li Y, Willer CJ, Ding J, Scheet P, Abecasis GR,. MaCH: Using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genet Epidemiol 2010; 34 (8): 816-834.
19. The International HapMap Consortium. A haplotype map of the human genome. Nature 2005; 437 (7063): 1299-1320.
20. Thorisson GA, Smith AV, Krishnan L, Stein LD,. The International HapMap Project Web site. Genome Res 2005; 15 (11): 1592-1593.
21. Li H, Kantoff PW, Giovannucci E, Leitzmann MF, Gaziano JM, Stampfer MJ, Ma J,. Manganese superoxide dismutase polymorphism, prediagnostic antioxidant status, and risk of clinical significant prostate cancer. Cancer Res 2005; 65 (6): 2498-2504.
22. Meplan C, Nicol F, Burtle BT, Crosley LK, Arthur JR, Mathers JC, Hesketh JE,. Relative abundance of selenoprotein P isoforms in human plasma depends on genotype, se intake, and cancer status. Antioxid Redox Signal 2009; 11 (11): 2631-2640.